LOWER GWYNEDD, PA — ChromaTan announced it has been awarded a $2 million grant from the National Institute of General Medical Sciences (NIGMS) to further develop its BioRMB™ technology. This grant supports the company’s mission to enhance biologics manufacturing while reducing costs and environmental impact.
The project will focus on developing purification processes for two adeno-associated virus (AAV) serotypes, sourced from ChromaTan’s commercial partners. It aims to improve both the capture and polishing stages, specifically targeting the separation of empty and full AAV particles. The BioRMB™ platform will be scaled up for pilot and large-scale current good manufacturing practice (cGMP) production.
“The BioRMB™ platform represents next-generation bioprocessing technology,” said Oleg Shinkazh, Chief Technical Officer at ChromaTan. “It offers significant improvements in manufacturability, process economics, recovery, and product quality. This grant empowers us to integrate these hyper-efficient platforms and potentially transform gene therapy manufacturing.”
ChromaTan’s initiative aims to advance biomanufacturing through innovative solutions. The company’s efforts aim to streamline production processes, making them more efficient and sustainable, which could revolutionize the field of gene therapy.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.